Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is adjuvant therapy for stage II colon cancer worthwhile, and for whom?

Nature Clinical Practice Gastroenterology & Hepatology volume 5, pages 422–423 (2008)Cite this article

QUASAR Collaborative Group (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370: 2020–2029

Background

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. No authors listed (1999) Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 17: 1356–1363

  2. Moertel CG et al. (1995) Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 13: 2936–2943

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jim Casey, Editorial Assistant, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. in the Division of Solid Tumor Oncology at the Memorial Sloan-Kettering Cancer Center, NH Segal is a Clinical Assistant Attending Physician and Instructor in Medicine, and LB Saltz is an Attending Physician and Professor of Medicine, New York, NY, USA.,

    Neil H Segal & Leonard B Saltz

Authors
  1. Neil H Segal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leonard B Saltz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leonard B Saltz.

Ethics declarations

Competing interests

NH Segal declared no competing interests. LB Saltz is a Consultant for and has received research/grant support from Genentech, Imclone, Merck and Pfizer. He has also received research/grant support from Amgen, Bayer and Taiho.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Segal, N., Saltz, L. Is adjuvant therapy for stage II colon cancer worthwhile, and for whom?. Nat Rev Gastroenterol Hepatol 5, 422–423 (2008). https://doi.org/10.1038/ncpgasthep1181

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep1181

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing